Evaluating the Effect of Taladafil on the Treatment of Severe Asthma

Phase 3

Recruiting

• Conditions: Asthma.; Asthma

• Registration Number: IRCT20200823048482N1
• Lead Sponsor: Ahvaz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 6 October 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

The Patients with Severe Asthma

Exclusion Criteria

Mild to moderate severity
Using Immunosuppressive Drug and Corticosteroid ( Greater than 5 mg Dose) Outside the Study Protocol in Three Months Ago
Advanced Liver Failure (Liver Cirrhosis), Advanced Renal Failure (CKD Stage 4,5)
Pregnancy
Uncontrolled Hypertension
Havingany Untreated Disease such as Reflux, Sinusitis or Allergic Bronchopulmonary Aspergillosis (ABPA) based on History and Paraclinical Tests which Trigger Asthma Exacerbation Continuously
Prohibition of Phosphodiesterase Inhibitors and Nitrate Consumption

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
ung Volume (Forced expiratory volume in one second); (FEV1). Timepoint: In the First Referral and One Month Later. Method of measurement: Spirometry Test.;Lung Volume (Forced Vital Capacity); (FVC). Timepoint: In the First Referral and One Month Later. Method of measurement: Spirometry Test.;Lung Volume (Forced Expiratory flow 25_75%); (FEF25-75%). Timepoint: In the First Referral and One Month Later. Method of measurement: Spirometry Test.;Forced Expiratory Volume in 1 Second to Forced Vital Capacity (FEV1/FVC). Timepoint: In the First Referral and One Month Later. Method of measurement: Spirometry Test.;Quality of Life Score (Upon Quality of Life Questionnaire in Asthmatic Patients). Timepoint: In the First Referral and One Month Later. Method of measurement: Questionnaire.